Clinical trial
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell…
NCT02631044 · Juno Therapeutics, a Subsidiary of Celgene, Industry · Completed
Key facts
| NCT number | NCT02631044 |
|---|---|
| Title | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) |
| Official title | A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) |
| Lead sponsor | Juno Therapeutics, a Subsidiary of Celgene, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma, Primary Mediastinal B-cell Lymphoma |
| Intervention type | Biological |
| Interventions | JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule |
| Enrollment | 387 |
| Start date | Jan 6, 2016 |
| Primary completion | May 16, 2024 |
| Completion | May 16, 2024 |
| First posted | Dec 15, 2015 |
| Last update posted | Jun 27, 2024 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: